Hurdles to HIV Survival
Why are so many patients still dying too young?
Roisin McGuigan |
A recent study in The Lancet has reported that – thanks to the latest HIV drugs – young adults with the virus can now enjoy a near-normal life expectancy. Today, a 20-year-old who began antiretroviral therapy (ART) in the last few years is estimated to live 10 years longer than a 20-year-old who began ART between 1996 and 1999. But for many patients, barriers to treatment prevent access to this increased life expectancy.
“I became involved in studying HIV survival in the first job I had after my master’s degree,” says Adam Trickey, lead author of the associated paper (1). “The Antiretroviral Therapy Cohort Collaboration is one of the largest HIV cohorts in the world, an enormous network across the US and Europe that has been running for more than a decade and contains over 100,000 patients – so I leapt at the opportunity to work with them,” he says. “Despite being new to the field when I started working on this paper, I was able to quickly learn the ropes as my many co-authors are all world-leading academics and clinicians in this area, with thousands of peer-reviewed publications between them.”
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!